Finix Tablet (Enteric Coated) EC Tablet 20 mg is a Product of the Generic Rabeprazole Sodium

What Is Finix Tablet (Enteric Coated) EC Tablet 20 mg Indications and Uses?

Finix is indicated for the treatment of: Active duodenal ulcer Active benign gastric ulcer Symptomatic erosive or ulcerative gastro-esophageal reflux disease (GERD). Gastro-esophageal Reflux Disease Long-term Management (GERD Maintenance) Symptomatic treatment of moderate to very severe gastro-esophageal reflux disease (symptomatic GERD) Zollinger-Ellison Syndrome In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori in patients with peptic ulcer disease.

Pharmacology (Source, Chemical and Physical Composition) Of Finix Tablet (Enteric Coated) EC Tablet 20 mg

Finix Tablet (Enteric Coated) EC Tablet 20 mg (Rabeprazole Sodium) suppresses gastric acid secretion by inhibiting the gastric H + /K + -ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, Rabeprazole has been characterized as a gastric proton-pump inhibitor.

Drug Interactions of Finix Tablet (Enteric Coated) EC Tablet 20 mg

Respite produces a profound and long-lasting inhibition of gastric acid secretion. An interaction with a compound whose absorption is pH dependent may occur. Co-administration of Finix with ketoconazole or itraconazole may result in a significant decrease in antifungal plasma levels. Therefore individual patients may need to be monitored to determine if a dosage adjustment is necessary when ketoconazole or itraconazole are taken concomitantly with Respite. No interaction with liquid antacids was observed. The absorption of atazanavir is pH-dependent. Therefore PPIs, including Finix Tablet (Enteric Coated) EC Tablet 20 mg (Rabeprazole Sodium), should not be co-administered with atazanavir.

Side Effects of Finix Tablet (Enteric Coated) EC Tablet 20 mg

In general, Finix is well-tolerated in both short-term and long-term studies. Finix may sometimes cause headache, diarrhoea, abdominal pain, vomiting, constipation, dry mouth, increased or decreased appetite, muscle pain, drowsiness, dizziness.

Precautions And Warnings for Finix Tablet (Enteric Coated) EC Tablet 20 mg

Symptomatic response to therapy with Finix does not preclude the presence of gastric or oesophageal malignancy, therefore the possibility of malignancy should be excluded prior to commencing treatment with Finix 20 mg Gastro-resistant Tablets. Patients on long-term treatment (particularly those treated for more than a year) should be kept under regular surveillance. Proton pump inhibitors, especially if used in high doses and over long durations (>1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10–40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care and they should have an adequate intake of vitamin D and calcium. A risk of cross-hypersensitivity reactions with other proton pump inhibitor or substituted benzimidazoles cannot be excluded. Patients should be cautioned that Finix gastro-resistant tablets should not be chewed or crushed, but should be swallowed whole. There have been post marketing reports of blood dyscrasias (thrombocytopenia and neutropenia). In the majority of cases where an alternative aetiology cannot be identified, the events were uncomplicated and resolved on discontinuation of Finix Tablet (Enteric Coated) EC Tablet 20 mg (Rabeprazole Sodium). Hepatic enzyme abnormalities have been seen in clinical trials and have also been reported since market authorisation. In the majority of cases where an alternative aetiology cannot be identified, the events were uncomplicated and resolved on discontinuation of rabeprazole. No evidence of significant drug related safety problems was seen in a study of patients with mild to moderate hepatic impairment versus normal age and sex matched controls. However because there are no clinical data on the use of rabeprazole in the treatment of patients with severe hepatic dysfunction the prescriber is advised to exercise caution when treatment with Finix 20mg Gastro-resistant. Tablets is first initiated in such patients. Co-administration of atazanavir with Finix is not recommended. Treatment with proton pump inhibitors, including rabeprazole, may possibly increase the risk of gastrointestinal infections such as Salmonella, Campylobacter and Clostridium difficile. Hypomagnesaemia : Severe hypomagnesaemia has been reported in patients treated with PPIs like rabeprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI. For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g., diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment. Influence on vitamin B12 absorption : Finix, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or a- chlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy or if respective clinical symptoms are observed. Subacute cutaneous lupus erythematosus (SCLE) : Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Finix. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors. Interference with laboratory tests : Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Finix 20mg Gastro-resistant Tablets treatment should be stopped for at least 5 days before CgA measurements. If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.

Use During Pregnancy and Lactation

US FDA pregnancy category 'C'. Studies have been performed in animals and have revealed no evidence of impaired fertility or harm to the fetus due to Finix Tablet (Enteric Coated) EC Tablet 20 mg (Rabeprazole Sodium). There are however, no adequate and well-controlled studies in pregnant women. Rabeprazole is likely to be excreted in human milk, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Therapeutic Class

Proton Pump Inhibitor

Storage Conditions of It

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.